Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1)

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a revolutionary class of drugs with far-reaching protective effects in multiple organs. The protective potential of SGLT2i is much broader than that of the classical concept of glucose control and consists of an entire conglomerate of associated pleiotropic effects. This study aims to provide a descriptive review of the pleiotropic therapeutic potential of SGLT2i. The first part of the literature review examined the use of SGLT2i in cardiology and nephrology. The use of SGLT2i represents an innovative approach to improving patients’ quality of life and course of heart failure and chronic kidney disease, regardless of left ventricular ejection fraction and type 2 diabetes.

Authors

Institutions

Publication Details

Journal
Innovative medicine of Kuban
Published
2024-11-15
DOI
https://doi.org/10.35401/2541-9897-2024-9-4-126-135
Citations
5
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
1.79
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1)

F. M. Khamidova, L. A. Martemyanova, Tamara R. Gevorgyan, Nizal Sarrafzadegan et al.
5 citations
Innovative medicine of Kuban
Diabetes Treatment and Management
1.79
article

Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1)

F. M. Khamidova, L. A. Martemyanova, Tamara R. Gevorgyan, Nizal Sarrafzadegan, Anahit Z. Aznauryan, Anna R. Petrosyan, Mohammad Sheibani, Karmen Sahakyan, Nana Pogosova, О. И. Уразова, А. И. Трофименко, L. M. Sukiasyan, Ashot Avagimyan, Marina R. Tatoyan, Evgenii E. Lysov, Gayne Mkrtchyan, Ruzanna Petrosyan, Goharik L. Meltonyan
article en
5 citations

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a revolutionary class of drugs with far-reaching protective effects in multiple organs. The protective potential of SGLT2i is much broader than that of the classical concept of glucose control and consists of an entire conglomerate of associated pleiotropic effects. This study aims to provide a descriptive review of the pleiotropic therapeutic potential of SGLT2i. The first part of the literature review examined the use of SGLT2i in cardiology and nephrology. The use of SGLT2i represents an innovative approach to improving patients’ quality of life and course of heart failure and chronic kidney disease, regardless of left ventricular ejection fraction and type 2 diabetes.

Innovative medicine of Kuban(4)
Isfahan University of Medical Sciences (IR), Peoples' Friendship University of Russia (RU), Iran University of Medical Sciences (IR), Kuban State Medical University (RU), Gomel State Medical University (BY), Siberian State Medical University (RU), Samarkand State Medical Institute (UZ), Lebanese American University (LB), Yerevan State Medical University (AM)
Openalex Percentile: Top 13%
Diabetes Treatment and Management
1.79
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.